A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors have a slightly lower risk of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback